Approval · Notice of Compliance 6032 · 2004
GLEEVEC: Notice of Compliance 6032
Issued December 29, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6032
- Date
- December 29, 2004
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update for new clinical data for 2nd line chronic myeloid leukemia (cml)
- Therapeutic class
- Protein tyrosine-kinase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GLEEVEC | Not yet assigned | — |
Medicinal ingredients
- IMATINIB MESYLATE 100 MG per TAB
- IMATINIB MESYLATE 400 MG per TAB
- IMATINIB MESYLATE 50 MG per CAP
- IMATINIB MESYLATE 100 MG per CAP